Evidence map›Paper›PMID 33791740›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Alpha-1 blockers and susceptibility to COVID-19 in benign prostate hyperplasia patients : an international cohort study.

Akihiko Nishimura, Junqing Xie, Kristin Kostka, Talita Duarte-Salles, Sergio Fernández Bertolín, María Aragón, Clair Blacketer, Azza Shoaibi, Scott L DuVall, Kristine Lynch and 16 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 14 institutions in 7 countries.

Akihiko NishimuraJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Junqing XieCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University, Oxford, UK.
Kristin KostkaReal World Solutions, IQVIA, Cambridge, MA, USA.
Talita Duarte-SallesFundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
Sergio Fernández BertolínFundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
María AragónFundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
Clair BlacketerObservational Health Data Analytics, Janssen Research and Development, Titusville, NJ, USA.
Azza ShoaibiObservational Health Data Analytics, Janssen Research and Development, Titusville, NJ, USA.
Scott L DuVallVA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.
Kristine LynchVA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.
Michael E MathenyTennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, TN, USA.
Thomas FalconerDepartment of Biomedical Informatics, Columbia University, New York, USA.
Daniel R MoralesDivision of Population Health and Genomics, University of Dundee, UK.
Mitchell M ConoverObservational Health Data Analytics, Janssen Research and Development, Titusville, NJ, USA.
Seng Chan YouDepartment of Preventive Medicine and Public Health, Yonsei University College of Medicine, Seoul, Korea.
Nicole PrattQuality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
James WeaverObservational Health Data Analytics, Janssen Research and Development, Titusville, NJ, USA.
Anthony G SenaObservational Health Data Analytics, Janssen Research and Development, Titusville, NJ, USA.
Martijn J SchuemieObservational Health Data Analytics, Janssen Research and Development, Titusville, NJ, USA.
Jenna RepsObservational Health Data Analytics, Janssen Research and Development, Titusville, NJ, USA.
Christian ReichReal World Solutions, IQVIA, Cambridge, MA, USA.
Peter R RijnbeekDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.
Patrick B RyanObservational Health Data Analytics, Janssen Research and Development, Titusville, NJ, USA.
George HripcsakDepartment of Biomedical Informatics, Columbia University, New York, USA.
Daniel Prieto-AlhambraCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University, Oxford, UK.
Marc A SuchardDepartment of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA.
Janssen (United States) · USInstitut Universitari d'Investigació en Atenció Primària Jordi Gol · ESColumbia University · USErasmus MC · NLNuffield Orthopaedic Centre · GBUniversity of California, Los Angeles · USUniversity of Utah · USIQVIA (United States) · USJohns Hopkins University · USNortheastern University · USUniversity of Dundee · GBUniversity of South Australia · AUVA Tennessee Valley Healthcare System · USYonsei University · KR

Funding

DISCOVERING AND APPLYING KNOWLEDGE IN CLINICAL DATABASESR01LM006910 · NLM · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HRIPCSAK, GEORGE M · 2000 to 2023
$10.6M
Gates Foundation INV-016201NLM NIH HHS R01 LM006910Wellcome Trust
6 · The paper itself

Abstract

Alpha-1 blockers, often used to treat benign prostate hyperplasia (BPH), have been hypothesized to prevent COVID-19 complications by minimising cytokine storms release. We conducted a prevalent-user active-comparator cohort study to assess association between alpha-1 blocker use and risks of three COVID-19 outcomes: diagnosis, hospitalization, and hospitalization requiring intensive services. Our study included 2.6 and 0.46 million users of alpha-1 blockers and of alternative BPH therapy during the period between November 2019 and January 2020, found in electronic health records from Spain (SIDIAP) and the United States (Department of Veterans Affairs, Columbia University Irving Medical Center, IQVIA OpenClaims, Optum DOD, Optum EHR). We estimated hazard ratios using state-of-the-art techniques to minimize potential confounding, including large-scale propensity score matching/stratification and negative control calibration. We found no differential risk for any of COVID-19 outcome, pointing to the need for further research on potential COVID-19 therapies.

Identifiers

PMID33791740
PMCPMC8010772
OpenAlexW3138704999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.